EICHORCondition: Myositis · Active Idiopathic Inflammatory Myopathy · Dermatomyositis · Sponsor: argenx
The main purpose of this study is to measure the long-term safety and tolerability of efgartigimod PH20 SC in adult participants with Idiopathic Inflammatory Myopathy (IIM) who previously participated in ARGX-113-2007. The study consists of a treatment period where participants will receive efgartigimod PH20 SC for up to 51 months. The treatment period will be followed by a treatment-free safety follow-up period of 56 days.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Neuromuscular Clinical and Research Center - Neurology | Phoenix, Arizona, United States | — |
| Attune Health Research, Inc | Beverly Hills, California, United States | — |
| UCI Health - ALS and Neuromuscular Center - Neurology | Orange, California, United States | — |
| UCSF Health - ALS and Neurodegenerative Disease Center - Dermatology | San Francisco, California, United States | — |
| Yale Cancer Center-Yale University School Of Medicine | New Haven, Connecticut, United States | — |
| UF Health - Rheumatology Medical Specialties Medical Plaza | Gainesville, Florida, United States | — |
| Mayo Clinic - Florida - Neurology | Jacksonville, Florida, United States | — |
| University of South Florida (USF) - Morsani Center (USF Health Carol and Frank Morsani Center for Advanced Healthcare) | Tampa, Florida, United States | — |
| Emory Healthcare - Emory Clinic - Rheumatology | Atlanta, Georgia, United States | — |
| Northwestern Medicine - Northwestern Memorial Hospital | Chicago, Illinois, United States | — |
| John Hopkins Medicine - Johns Hopkins Myositis Center | Baltimore, Maryland, United States | — |
| Northwell Health Physician Partners Rheumatology | Great Neck, New York, United States | — |
+ 80 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05979441